Kinoxis Therapeutics Pty Ltd

The University of Sydney

William Jorgensen

Michael Kassiou

Iain Stewart McGregor

Michael Thomas Bowen

Callum Hicks

Tristan Reekie

Lenka Munoz

Eryn Werry

Damien Gulliver

Timothy Katte

Iain Mcgregor

Disclosed herein are compounds, compositions and methods for the treatment of neurological, psychiatric disorders which are characterized by a fundamental disruption of social behaviour, and substance use disorders. In particular, disclosed herein are compounds of Formula (I), or salts or prodrugs thereof. Methods of treating or preventing neurological, psychiatric disorders and substance use disorders, using compounds of Formula (I), or salts and prodrugs are also disclosed.

Therapeutic compounds and compositions for treating social disorders and substance use disorders

The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).

Anti-cancer compounds

Disclosed herein are compounds according to Formula I; a pharmaceutical composition including, consisting essentially of, or consisting of: a pharmaceutically acceptable compound of Formula I and a pharmaceutically acceptable carrier, diluent, or excipient; the use of compounds of Formula I in the preparation of a medicament; and a method including administering a pharmaceutical compositions comprising the compound of Formula I to a patient. The compounds, compositions, use, and methods are directed to the treatment of neurological, psychiatric disorders which are characterised by a fundamental disruption of social behaviour, and substance use disorders.

Non-peptide oxytocin receptor agonists

The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer). In some embodiments, the present invention relates to compounds of formula (I):  or pharmaceutically acceptable salts or prodrugs thereof.

The present disclosure relates to compounds of Formula I being cyclic metabolites of oxytocin. These derivatives have enhanced selectivity for the oxytocin receptor.

Metabolite inspired selective oxytocin receptor agonists

Disclosed herein are compounds, compositions and methods for the treatment of neurological, psychiatric disorders which are characterised by a fundamental disruption of social behaviour, and substance use disorders. In particular, disclosed herein are compounds of Formula (I), or salts or prodrugs thereof. Methods of treating or preventing neurological, psychiatric disorders and substance use disorders, using compounds of Formula (I), or salts and prodrugs are also disclosed.

Growing community of inventors

New South Wales, Australia

William Jorgensen